Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Oruka Therapeutics › CEO exercised or converted 25K ORKA derivative securities Insider trades
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Nov 2, 2026
Reporting period Not applicable
Filed with the SEC Nov 2, 2026 CEO Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0000907654-26-000112
Filed / recorded
Nov 2, 2026, 10:46 PM UTC
Added to OQRO Nov 2, 2026, 10:50 PM UTC
Data quality Verified: identifiers matched exactly
Issuer Oruka Therapeutics, Inc.
Reporting person Lawrence Otto Klein
Relationship Director, Officer
Officer title Chief Executive Officer
Table Non-derivative (Table I)
Transaction date Nov 2, 2026
Acquired / disposed Acquired (A)
Shares owned after 948,128 The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Oct 1, 2026 Insider · 1 person Insiders: 3 sales (~$2.1M) Oct 12, 2026 Insider · 1 person Insiders: 4 sales (~$806K) Oct 15, 2026 Insider · 1 person Insiders: 5 sales (~$524K) Oct 20, 2026 Insider · 1 person Insiders: 5 sales (~$707K) Nov 2, 2026 Insider · 1 person Insiders: 5 sales (~$2.4M) What came next Nov 12, 2026 Insider · 2 people Insiders: 12 sales (~$2.9M) Nov 16, 2026 5% stake RTW Investments, LP reported a passive stake (13G) of 4.7% Nov 16, 2026 5% stake T. Rowe Price Investment Management, Inc. reported a passive stake (13G) of 6.6% Nov 16, 2026 Insider · 1 person
Insiders: 6 sales (~$707K)